ArticleERJ open research2025
Long-term outcomes of Qing-Dai-induced pulmonary arterial hypertension.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Qing-Dai (indigo naturalis), which is used to treat inflammatory bowel disease in Japan, has been linked to pulmonary arterial hypertension (PAH) and is recognised in the 2022 European Society of Cardiology/European Respiratory Society guidelines as a drug associated with PAH. However, the long-term clinical course of Qing-Dai-induced PAH has not been studied. Methods: This retrospective multicentre study included 20 patients diagnosed with PAH after Qing-Dai use in Japan between 2011 and 2024. Haemodynamic data were collected when PAH was diagnosed, within 1 year after Qing-Dai discontinuation and at the final follow-up evaluation. To elucidate the underlying mechanisms, we analysed the composition of Qing-Dai and examined its effects on vascular endothelial cells. Results: The study cohort comprised 11 female and nine male patients (median age: 40 years; range: 19-70 years). The median duration of Qing-Dai exposure before PAH was diagnosed was 4.8 years (range: 0.5-15 years). Discontinuation of Qing-Dai and the use of PAH medications were associated with significant improvement in haemodynamic parameters. The mean pulmonary arterial pressure decreased from 52.5 to 25.0 mmHg, and the median pulmonary vascular resistance decreased from 10.8 to 2.6 Wood units. Six (30%) patients discontinued PAH medication and remained recurrence-free. One patient experienced PAH relapse after discontinuation of PAH medications. Seven (35%) patients exhibited persistent PAH despite treatment. A mass spectrometry analysis of Qing-Dai identified indirubin, which was found to induce endothelial apoptosis. Conclusion: Discontinuation of Qing-Dai is important to PAH management. Routine follow-up is necessary to monitor potential recurrence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.